New hope for stubborn nerve disorder: drug combo shows promise

This study tests whether adding telitacicept to standard therapy helps adults with refractory chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. About 76 participants will receive either standard care alone or standard care plus telitacicept for 24 weeks. Researchers will measure improvements in disability, strength, and mobility, and monitor side effects.